VERTEX PHARMACEUTICALS INC / MA (VRTX)
↓ Download CSV- Sector Manufacturing
- Incorporated MA
- Fiscal year ends Dec 31
In fiscal 2025, VERTEX PHARMACEUTICALS INC / MA reported revenue of $12.00B, up 8.9% from the prior year. The company was profitable, with a net margin of 32.9%. It held $25.64B in total assets against $6.98B in total liabilities.
Key ratios (FY2025)
34.8%
Operating margin
32.9%
Net margin
21.2%
Return on equity
+8.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B | $4.16B | $3.05B | $2.49B | $1.70B |
| Cost of Revenue | $1.65B | $1.53B | $1.26B | $1.08B | $904.20M | $736.30M | $547.80M | $409.54M | $275.12M | $210.46M |
| Operating Income | $4.17B | -$232.90M | $3.83B | $4.31B | $2.78B | $2.86B | $1.20B | $635.15M | $123.24M | $9.94M |
| Net Income | $3.95B | -$535.60M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B | $2.10B | $263.48M | -$112.05M |
| EPS (Diluted) | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | $-0.46 |
| Total Assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B | $11.75B | $8.32B | $6.25B | $3.55B | $2.90B |
| Total Liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B | $3.06B | $2.23B | $1.81B | $1.50B | $1.56B |
| Shareholders' Equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B | $8.69B | $6.09B | $4.44B | $2.03B | $1.16B |
| Cash & Equivalents | $5.08B | $4.57B | $10.37B | $10.50B | $6.79B | $5.99B | $3.11B | $2.65B | $1.67B | $1.18B |
| Operating Cash Flow | $3.63B | -$492.60M | $3.54B | $4.13B | $2.64B | $3.25B | $1.57B | $1.27B | $844.94M | $236.10M |
| Capital Expenditures | $437.60M | $297.70M | $200.40M | $204.70M | $235.00M | $259.80M | $75.40M | $95.45M | $99.42M | $56.56M |
| Shares Outstanding | 258.00M | 257.90M | 260.50M | 259.10M | 259.90M | 263.40M | 260.70M | 259.19M | 253.22M | 244.69M |